logo
Plus   Neg
Share
Email

Innoviva, GSK: EU Approves Label Update To Relvar Ellipta In Asthma Patients

Innoviva, Inc. (INVA) and GlaxoSmithKline plc (GSK,GSK.L) announced Thursday that the European Commission has approved a label update to Relvar Ellipta in patients with asthma.

The label update is for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting ß2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ß2-agonist.

The updated marketing authorisation by the European Commission will be reflected in the label for Relvar Ellipta for countries in the European Union.

The company said the Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function. No new safety signals were identified and the adverse event data were consistent with the known safety profile for FF/VI established in patients with asthma.

Jonathan Sweeting, SVP and Head of Global Respiratory Franchise GSK, said: "Patients with asthma can continue to experience symptoms despite being adequately controlled and these symptoms can impact their lives. This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BMW plans to shut down the Mini factory in Oxford for a month after Brexit to minimize supply disruption in case there is no deal. The German auto giant said its annual maintenance shutdown at the site in Cowley, Oxford will be brought forward to April 1 to reduce any "possible short-term parts-supply... Tech giant Apple Inc.'s (AAPL) smart watch and wireless headphones will not be affected by the Trump administration's latest tariffs on Chinese imports. Apple Watches and AirPods has been added on a list of 300 products that are exempt from the latest tariffs. The Trump administration has imposed... Visa Inc., Mastercard Inc. and some U.S. banks have agreed to pay $6.2 billion settle a class-action lawsuit over card swipe fees. The antitrust lawsuit was brought by U.S. retailers in 2005 over the fees they pay when they accept card payments. The settlement, the largest ever of an antitrust case, is an amendment to the financial terms of the 2012 Class Settlement Agreement.
Follow RTT